Be the first to like this
IntroductionDriven by the launch of disease modifying treatments and an expanding patient population, the Alzheimer's disease market will more than double over the next 10 years. Late-stage pipeline …
IntroductionDriven by the launch of disease modifying treatments and an expanding patient population, the Alzheimer's disease market will more than double over the next 10 years. Late-stage pipeline products such as Pfizer/Medivation's Dimebon (latrepirdine) and Johnson & Johnson/Wyeth's bapineuzumab hold blockbuster potential. However, the risk of clinical trial failure remains high in this indication.Scope*Forecasts to 2018 for Alzheimer's disease, total dementia, and mild cognitive impairment for novel disease-modifying agents in the seven major markets*Forecasts to 2018 of current brand reformulations targeting the symptomatic relief market.*Provides a global Alzheimer's disease market snapshot, and analysis of patient population growth trends in the seven major markets and BRIC nations.*Discusses the requirement for biomarker development and targeting patients earlier in the course of their disease.HighlightsWith impressive Phase II data, a strong marketing partner, and broad target population, Datamonitor forecasts multi-billion dollar sales for Pfizer and Medivation's Dimebon (latrepirdine) over the forecast period 20092018.Driven by prescribing in non-ApoE4 allele patients, Datamonitor forecasts lucrative sales for Johnson & Johnson/Wyeth's bapineuzumab. Off-label prescribing for pre-dementia/prodromal Alzheimer's disease type mild cognitive impairment patients will add significant revenue towards the end of the 10-year outlook.It is unlikely that a treatment will be developed which completely halts, or reverse, the cognitive decline observed in Alzheimer's disease over the 10 year time horizon. Therefore, a symptomatic market will remain active in this disease over the forecast period.Reasons to Purchase*Quantify the current size of the global Alzheimer's disease market.*Appreciate the demographic changes leading to anticipated growth in the Alzheimer's disease market.*Quantify the market to 2018 in the US, Japan, and five key European markets while identifying the major drivers, resistors, and risks.